Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741–66.

Article  CAS  PubMed  Google Scholar 

Glenner GG, Wong CW. Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun. 1984;122:1131–5.

Article  CAS  PubMed  Google Scholar 

Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA. 1985;82:4245–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The Amyloid-beta Pathway in Alzheimer’s Disease. Mol Psychiatry. 2021;26:5481–503.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8:595–608.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beyreuther K, Masters CL. Amyloid precursor protein (APP) and beta A4 amyloid in the etiology of Alzheimer’s disease: precursor-product relationships in the derangement of neuronal function. Brain Pathol. 1991;1:241–51.

Article  CAS  PubMed  Google Scholar 

Selkoe DJ. The molecular pathology of Alzheimer’s disease. Neuron. 1991;6:487–98.

Article  CAS  PubMed  Google Scholar 

Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharm Sci. 1991;12:383–8.

Article  CAS  PubMed  Google Scholar 

Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256:184–5.

Article  CAS  PubMed  Google Scholar 

Kumar M, Cohen D, Eisdorfer C. Serum IgG brain reactive antibodies in Alzheimer disease and Down syndrome. Alzheimer Dis Assoc Disord. 1988;2:50–55.

Article  CAS  PubMed  Google Scholar 

Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci USA. 1996;93:452–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA. 1997;94:4109–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schenk D. Hopes remain for an Alzheimer’s vaccine. Nature. 2004;431:398.

Article  CAS  PubMed  Google Scholar 

Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61:46–54.

Article  CAS  PubMed  Google Scholar 

Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer’s disease. J Neurosci. 2005;25:6213–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N. Engl J Med. 2014;370:322–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther. 2017;9:95.

Article  PubMed  PubMed Central  Google Scholar 

Ostrowitzki S, Bittner T, Sink KM, Mackey H, Rabe C, Honig LS, et al. Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials. JAMA Neurol. 2022;79:1113–21.

Article  PubMed  PubMed Central  Google Scholar 

Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimer’s Dement. 2021;17:696–701.

Article  Google Scholar 

Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer’s Disease. N. Engl J Med. 2014;370:311–21.

Article  CAS  PubMed  Google Scholar 

Kepp KP, Robakis NK, Høilund-Carlsen PF, Sensi SL, Vissel B. The amyloid cascade hypothesis: an updated critical review. Brain. 2023;146:3969–90.

Article  PubMed  Google Scholar 

Alexander GC, Knopman DS, Emerson SS, Ovbiagele B, Kryscio RJ, Perlmutter JS, et al. Revisiting FDA Approval of Aducanumab. N. Engl J Med. 2021;385:769–71.

Article  CAS  PubMed  Google Scholar 

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer’s Disease. N. Engl J Med. 2023;388:9–21.

Article  PubMed  Google Scholar 

Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330:512–27.

Article  CAS  PubMed  Google Scholar 

Rosenberg RN, Lambracht-Washington D, Yu G, Xia W. Genomics of Alzheimer Disease: A Review. JAMA Neurol. 2016;73:867–74.

Article  PubMed  PubMed Central  Google Scholar 

Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive. Nature. 2012;488:96–99.

Article  CAS  PubMed  Google Scholar 

Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N. Engl J Med. 2012;367:795–804.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang HF, Shen XN, Li JQ, Suckling J, Tan CC, Wang YJ, et al. Clinical and biomarker trajectories in sporadic Alzheimer’s disease: A longitudinal study. Alzheimers Dement. 2020;12:e12095.

Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci. 2012;15:349–57.

Article  CAS  PubMed  Google Scholar 

CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761178Orig1s000ClinPharm_Redacted.pdf, 2021, Accessed Date Accessed 2021.

Liu YH, Giunta B, Zhou HD, Tan J, Wang YJ. Immunotherapy for Alzheimer disease: the challenge of adverse effects. Nat Rev Neurol. 2012;8:465–9.

Article  CAS  PubMed  Google Scholar 

Wang X. A Bridge Between the Innate Immunity System and Amyloid-β Production in Alzheimer’s Disease. Neurosci Bull. 2021;37:898–901.

Article  PubMed  PubMed Central  Google Scholar 

Bertram L, Tanzi RE. Alzheimer disease risk genes: 29 and counting. Nat Rev Neurol. 2019;15:191–2.

Article  PubMed  Google Scholar 

Sarlus H, Heneka MT. Microglia in Alzheimer’s disease. J Clin Investig. 2017;127:3240–9.

Article  PubMed  PubMed Central  Google Scholar 

Franco-Bocanegra DK, McAuley C, Nicoll JAR, Boche D. Molecular Mechanisms of Microglial Motility: Changes in Ageing and Alzheimer’s Disease. Cells. 2019;8:639.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen X, Holtzman DM. Emerging roles of innate and adaptive immunity in Alzheimer’s disease. Immunity. 2022;55:2236–54.

Article  CAS  PubMed  Google Scholar 

Fan DY, Wang YJ. Early Intervention in Alzheimer’s Disease: How Early is Early Enough? Neurosci Bull. 2020;36:195–7.

Article  CAS  PubMed  Google Scholar